⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

April 5, 2024Future Medicinal ChemistryOpen Access

Design, synthesis and evaluation of new thiazolidin-4-ones as LPA ₁ receptor antagonists for breast cancer therapy

Meduri Bhagyalalitha Pavan SR Ashwini Prabhu Akshatha HS Sethu Arun Kumar Manisha Singh Karthik G. Pujar Gurubasavaraj V. Pujar

View Full Paper

Ask AI

Bookmark

Share

Abstract

Breast cancer has been a leading cause of mortality among women worldwide in recent years. Targeting the lysophosphatidic acid (LPA)-LPA

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bhagyalalitha et al. (2024) studied this question.

synapsesocial.com/papers/68e70542b6db64358767ece4 https://doi.org/10.4155/fmc-2023-0333

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Abstract 7491: LPA1 antagonists as potential migrastatics for triple negative breast cancerOriginal Research · 2026
2Lysophosphatidic Acid Receptor 1 (LPA<sub>1</sub>) Antagonists as Potential Migrastatics for Triple Negative Breast Cancer2024 · 2 citations
34‐Thiazolidinone Derivatives as PARP‐1 Inhibitors Targeting Breast Cancer: Integrating DFT, Molecular Docking, Molecular Dynamics Simulations, and ADMETox AnalysisOriginal Research · 2026
4Design, synthesis, and multi-target anticancer evaluation of 1,3-thiazolodin-4-one analogues against breast cancer: mechanistic insights into estrogen metabolism, inflammation, angiogenesis, and oxidative stressOriginal Research · 2026 · 6 citations
5Integrated computational and preclinical evaluation of novel synthetic pyrazole pyrazoline thiazole derivative for breast cancer therapeutics2025 · 4 citations